BELLUS HEALTH INC Inactive Instrument
BELLUS Health Inc Share Price Toronto S.E.
Equities
CA07987C1059
Biotechnology & Medical Research
| Sales 2021 | 16K 11.71K 938K | Sales 2022 | 16K 11.71K 938K | Capitalization | 1.03B 757M 60.62B |
|---|---|---|---|---|---|
| Net income 2021 | -71M -51.94M -4.16B | Net income 2022 | -76M -55.6M -4.45B | EV / Sales 2021 | 36,461 x |
| Net cash position 2021 | 248M 181M 14.53B | Net cash position 2022 | 336M 246M 19.68B | EV / Sales 2022 | 43,652 x |
| P/E ratio 2021 |
-8.96
x | P/E ratio 2022 |
-12.4
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 81.52% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Roberto Bellini
CEO | Chief Executive Officer | 44 | 04/06/09 |
Jeremy Martin
PSD | President | - | - |
| Chairman | 77 | 31/12/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 77 | 31/12/01 | |
Franklin Berger
BRD | Director/Board Member | 74 | 30/04/10 |
| Director/Board Member | 52 | 31/05/09 |
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
